



ASX Announcement

25 September 2026

Date of AGM and Closing Date for Director Nominations

In accordance with ASX Listing Rule 3.13.1, **Invex Therapeutics Limited** (ASX: IXC) (**Company**) advises that the Annual General Meeting of the Company will be held on Friday, 20 November 2026.

A notice of meeting for the Annual General Meeting (**AGM**) is being prepared by the Company and will be announced to ASX and provided to Shareholders in October 2026.

An item of business at the AGM will be the election of Directors. The closing date for the receipt of nominations for the election of Directors is Friday, 2 October 2026.

Any nominations must be received no later than 5:00pm (Perth time) on Friday, 2 October 2026 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting

This release dated 25 September 2026 has been authorised for lodgement to the ASX by Tim Slate, Company Secretary

ENDS

For more information, please contact:

Company/Investors

Mr David Wheeler
Non-Executive Director
+61 8 6558 0886

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com